CL2008000404A1 - Sal cristalina de napadisilato de 5-(2-[[6-(2,2-difluoro-2-feniletoxi)hexil]amino]-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como asma o epoc. - Google Patents

Sal cristalina de napadisilato de 5-(2-[[6-(2,2-difluoro-2-feniletoxi)hexil]amino]-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como asma o epoc.

Info

Publication number: CL2008000404A1
Authority: CL; Chile
Prior art keywords: phenyletoxi; hexil; napadisylate; hydroxyquinolin; crystaline
Prior art date: 2007-02-09

Application number

CL200800404A

Other languages

English (en)

Inventor

Puig Duran Enrique Moye Carlos

Original Assignee

Almirall Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-02-09

Filing date

2008-02-07

Publication date

2008-08-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39365949&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008000404(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-02-07 Application filed by Almirall Lab filed Critical Almirall Lab

2008-08-18 Publication of CL2008000404A1 publication Critical patent/CL2008000404A1/es

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Otolaryngology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Quinoline Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

CL200800404A 2007-02-09 2008-02-07 Sal cristalina de napadisilato de 5-(2-[[6-(2,2-difluoro-2-feniletoxi)hexil]amino]-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como asma o epoc. CL2008000404A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
ES200700362A ES2306595B1 (es)	2007-02-09	2007-02-09	Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.

Publications (1)

Publication Number	Publication Date
CL2008000404A1 true CL2008000404A1 (es)	2008-08-18

Family

ID=39365949

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200800404A CL2008000404A1 (es)	2007-02-09	2008-02-07	Sal cristalina de napadisilato de 5-(2-[[6-(2,2-difluoro-2-feniletoxi)hexil]amino]-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como asma o epoc.

Country Status (31)

Country	Link
US (1)	US8283342B2 (es)
EP (1)	EP2121615B1 (es)
JP (1)	JP5390402B2 (es)
KR (2)	KR20140140651A (es)
CN (1)	CN101679269B (es)
AR (1)	AR065247A1 (es)
AT (1)	ATE551323T1 (es)
AU (1)	AU2008213109B2 (es)
BR (1)	BRPI0806391A8 (es)
CA (1)	CA2677610C (es)
CL (1)	CL2008000404A1 (es)
CO (1)	CO6231025A2 (es)
CY (1)	CY1113366T1 (es)
DK (1)	DK2121615T3 (es)
EC (1)	ECSP099557A (es)
ES (2)	ES2306595B1 (es)
HR (1)	HRP20120456T1 (es)
IL (1)	IL199912A (es)
MX (1)	MX2009008462A (es)
MY (1)	MY153657A (es)
NZ (1)	NZ578412A (es)
PE (2)	PE20081752A1 (es)
PL (1)	PL2121615T3 (es)
PT (1)	PT2121615E (es)
RS (1)	RS52302B (es)
RU (1)	RU2495029C2 (es)
SI (1)	SI2121615T1 (es)
TW (1)	TWI396535B (es)
UA (1)	UA97829C2 (es)
WO (1)	WO2008095720A1 (es)
ZA (1)	ZA200904851B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6548540B2 (en) *	1998-09-08	2003-04-15	Charlotte-Mecklenburg Hospital Authority	Method of treating cancer using dithiocarbamate derivatives
ES2265276B1 (es) *	2005-05-20	2008-02-01	Laboratorios Almirall S.A.	Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2296516B1 (es) *	2006-04-27	2009-04-01	Laboratorios Almirall S.A.	Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2320961B1 (es) *	2007-11-28	2010-03-17	Laboratorios Almirall, S.A.	Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EP2096105A1 (en) *	2008-02-28	2009-09-02	Laboratorios Almirall, S.A.	Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor
UY32297A (es) *	2008-12-22	2010-05-31	Almirall Sa	Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2221055A1 (en) *	2009-02-18	2010-08-25	Almirall, S.A.	5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function
EP2221297A1 (en) *	2009-02-18	2010-08-25	Almirall, S.A.	5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one and its use in the treatment of pulmonary diseases
EP2226323A1 (en)	2009-02-27	2010-09-08	Almirall, S.A.	New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives
EP2228368A1 (en)	2009-03-12	2010-09-15	Almirall, S.A.	Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
WO2010130224A1 (zh)	2009-05-14	2010-11-18	天津和美生物技术有限公司	噻吩衍生物
WO2011061527A1 (en)	2009-11-17	2011-05-26	Astrazeneca Ab	Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
EP2338888A1 (en)	2009-12-24	2011-06-29	Almirall, S.A.	Imidazopyridine derivatives as JAK inhibitors
UY33213A (es)	2010-02-18	2011-09-30	Almirall Sa	Derivados de pirazol como inhibidores de jak
EP2360158A1 (en)	2010-02-18	2011-08-24	Almirall, S.A.	Pyrazole derivatives as jak inhibitors
EP2380890A1 (en)	2010-04-23	2011-10-26	Almirall, S.A.	New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors
EP2394998A1 (en)	2010-05-31	2011-12-14	Almirall, S.A.	3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors
EP2397482A1 (en)	2010-06-15	2011-12-21	Almirall, S.A.	Heteroaryl imidazolone derivatives as jak inhibitors
EP2441755A1 (en)	2010-09-30	2012-04-18	Almirall, S.A.	Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors
GB201016912D0 (en)	2010-10-07	2010-11-24	Astrazeneca Ab	Novel combination
EP2457900A1 (en)	2010-11-25	2012-05-30	Almirall, S.A.	New pyrazole derivatives having CRTh2 antagonistic behaviour
EP2463289A1 (en)	2010-11-26	2012-06-13	Almirall, S.A.	Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
EP2489663A1 (en)	2011-02-16	2012-08-22	Almirall, S.A.	Compounds as syk kinase inhibitors
EP2518071A1 (en)	2011-04-29	2012-10-31	Almirall, S.A.	Imidazopyridine derivatives as PI3K inhibitors
EP2518070A1 (en)	2011-04-29	2012-10-31	Almirall, S.A.	Pyrrolotriazinone derivatives as PI3K inhibitors
EP2527344A1 (en)	2011-05-25	2012-11-28	Almirall, S.A.	Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
EP2526945A1 (en)	2011-05-25	2012-11-28	Almirall, S.A.	New CRTH2 Antagonists
EP2548876A1 (en)	2011-07-18	2013-01-23	Almirall, S.A.	New CRTh2 antagonists
EP2548863A1 (en)	2011-07-18	2013-01-23	Almirall, S.A.	New CRTh2 antagonists.
EP2554544A1 (en)	2011-08-01	2013-02-06	Almirall, S.A.	Pyridin-2(1h)-one derivatives as jak inhibitors
EP2578570A1 (en)	2011-10-07	2013-04-10	Almirall, S.A.	Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2641900A1 (en) *	2012-03-20	2013-09-25	Almirall, S.A.	Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
EP2668941A1 (en)	2012-05-31	2013-12-04	Almirall, S.A.	Novel dosage form and formulation of abediterol
WO2014060431A1 (en)	2012-10-16	2014-04-24	Almirall, S.A.	Pyrrolotriazinone derivatives as pi3k inhibitors
EP2738172A1 (en)	2012-11-28	2014-06-04	Almirall, S.A.	New bicyclic compounds as crac channel modulators
UY35332A (es)	2013-02-15	2014-11-28	Almirall Sa	Derivados de pirrolotriazina como inhibidores de pi3k
EP2848615A1 (en)	2013-07-03	2015-03-18	Almirall, S.A.	New pyrazole derivatives as CRAC channel modulators
KR102398639B1 (ko) *	2017-06-20	2022-05-17	(주) 성운파마코피아	아미드 유도체의 염 및 그 제조방법
MX2020003578A (es) *	2017-10-13	2020-07-22	Treeway Tw001 B V	Sal de edaravone.

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AT334335B (de)	1973-03-01	1976-01-10	Basf Ag	Verfahren zur herstellung von 1-phenyl-2-aminoathanolen-(1)
US3053865A (en)	1958-03-19	1962-09-11	Merck & Co Inc	Novel 16-alkyl and 16-alkylene steroids and processes
GB869511A (en)	1958-05-26	1961-05-31	Upjohn Co	Improvements in or relating to steroids and the manufacture thereof
US3007923A (en)	1959-01-22	1961-11-07	Lab Francais Chimiotherapie	Process for the fluorination of 9beta, 11beta-epoxy and 5alpha, 6alpha-epoxy steroids
US3104246A (en)	1961-08-18	1963-09-17	Roussel Uclaf	Process of preparation of beta-methasone
GB1200886A (en)	1966-09-23	1970-08-05	Allen & Hanburys Ltd	Phenylaminoethanol derivatives
GB1247370A (en)	1968-12-31	1971-09-22	Allen & Hanburys Ltd	Glyoxals and production thereof
US3678137A (en)	1970-10-15	1972-07-18	Smith Kline French Lab	Adamantyl-substituted-alkyl 2-aminoethyl phosphates and phosphonates
BE786713A (fr)	1971-07-27	1973-01-25	Sandoz Sa	Nouveaux amino-alcools, leur preparation et leur application comme medicaments
SE378109B (es)	1972-05-19	1975-08-18	Bofors Ab
US4068076A (en)	1972-12-29	1978-01-10	Otsuka Pharmaceutical Co., Ltd.	5-(1-Hydroxy-2-(heterocyclic amino))ethyl-8-hydroxy-3,4-dihydrocarbostyril derivatives
US3975391A (en)	1973-12-26	1976-08-17	Otsuka Pharmaceutical Company Limited	5-[1-Hydroxy-2-(substituted-amino)]ethyl-8-hydroxy-3,4-dihydrocarbostyril derivatives
DE2310140A1 (de)	1973-03-01	1974-09-12	Basf Ag	Neue 1-phenyl-2-amino-aethanolderivate und ein verfahren zu ihrer herstellung
GB1468156A (en)	1973-07-19	1977-03-23	Ici Ltd	Phenylethylamine derivatives
US4026897A (en)	1974-01-31	1977-05-31	Otsuka Pharmaceutical Company	5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-hydroxycarbostyril derivatives
US4022784A (en)	1974-01-31	1977-05-10	Otsuka Pharmaceutical Company Limited	5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-substituted-carbostyril and -3,4-dihydrocarbostyril derivatives
JPS5649907B2 (es)	1974-02-01	1981-11-25
US4145542A (en)	1974-06-13	1979-03-20	Otsuka Pharmaceutical Co., Ltd.	5- 1-Hydroxy-2-(heterocyclic-amino)!alkyl-8-hydroxy-3,4-dihydrocarbostyril derivatives
US3994901A (en)	1974-06-13	1976-11-30	Otsuka Pharmaceutical Company Limited	5-[1-Hydroxy-2-(substituted-amino)]alkyl-8-hydroxy-3,4-dihydrocarbostyril derivatives
JPS597706B2 (ja)	1975-06-13	1984-02-20	オオツカセイヤクカブシキガイシヤ	カルボスチリルユウドウタイノセイゾウホウ
EP0006735B1 (en)	1978-06-28	1983-06-15	Beecham Group Plc	Secondary amines, their preparation, pharmaceutical compositions containing them and their use
IT7920688U1 (it)	1979-02-05	1980-08-05	Chiesi Paolo	Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore
CY1492A (en)	1981-07-08	1990-02-16	Draco Ab	Powder inhalator
ZW6584A1 (en)	1983-04-18	1985-04-17	Glaxo Group Ltd	Phenethanolamine derivatives
US4570630A (en)	1983-08-03	1986-02-18	Miles Laboratories, Inc.	Medicament inhalation device
JPS6010032B2 (ja)	1983-10-31	1985-03-14	大塚製薬株式会社	カルボスチリル誘導体
GB8334494D0 (en)	1983-12-24	1984-02-01	Tanabe Seiyaku Co	Carbostyril derivatives
NZ212367A (en)	1984-06-11	1989-04-26	Glaxo Group Ltd	Ethanolamine derivatives and pharmaceutical compositions
FI69963C (fi)	1984-10-04	1986-09-12	Orion Yhtymae Oy	Doseringsanordning
JPS6485964A (en)	1987-03-12	1989-03-30	Glaxo Group Ltd	Compound
DE3880628T2 (de)	1987-11-13	1993-08-05	Glaxo Group Ltd	Phenethanolamin-derivate.
DE3927170A1 (de)	1989-08-17	1991-02-21	Boehringer Ingelheim Kg	Inhalator
EP0416925A3 (en)	1989-09-07	1991-09-25	Glaxo Group Limited	Use of 4-hydroxy-alpha 1-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-1,3-benzenedimethanol or its salts in the treatment of allergy and inflammation
IT1237118B (it)	1989-10-27	1993-05-18	Miat Spa	Inalatore multidose per farmaci in polvere.
US5201308A (en)	1990-02-14	1993-04-13	Newhouse Michael T	Powder inhaler
GB9004781D0 (en)	1990-03-02	1990-04-25	Glaxo Group Ltd	Device
SG45171A1 (en)	1990-03-21	1998-01-16	Boehringer Ingelheim Int	Atomising devices and methods
GB9015522D0 (en)	1990-07-13	1990-08-29	Braithwaite Philip W	Inhaler
WO1992003175A1 (en)	1990-08-11	1992-03-05	Fisons Plc	Inhalation device
US5507281A (en)	1990-08-30	1996-04-16	Boehringer Ingelheim Kg	Device for initiating a mechanical switching operation in synchronism with the breathing
DE4027391A1 (de)	1990-08-30	1992-03-12	Boehringer Ingelheim Kg	Treibgasfreies inhalationsgeraet
GR1001529B (el)	1990-09-07	1994-03-31	Elmuquimica Farm Sl	Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
EP0640354B1 (en)	1990-09-26	2001-12-05	Pharmachemie B.V.	Whirl chamber powder inhaler
GB9026025D0 (en)	1990-11-29	1991-01-16	Boehringer Ingelheim Kg	Inhalation device
AU650953B2 (en)	1991-03-21	1994-07-07	Novartis Ag	Inhaler
DE4239402A1 (de)	1992-11-24	1994-05-26	Bayer Ag	Pulverinhalator
EP0674533B1 (en)	1992-12-18	1999-03-10	Schering Corporation	Inhaler for powdered medications
EP1366777B1 (en)	1995-04-14	2005-06-15	SmithKline Beecham Corporation	Metered dose inhaler for salmeterol
WO1997000703A1 (en)	1995-06-21	1997-01-09	Asta Medica Aktiengesellschaft	Pharmaceutical powder cartridge with integrated metering device and inhaler for powdered medicaments
DE19536902A1 (de)	1995-10-04	1997-04-10	Boehringer Ingelheim Int	Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
DE69738949D1 (de) *	1996-05-20	2008-10-09	Darwin Discovery Ltd	Chinolincarboxamide als tnf-inhibitoren und als pde-iv inhibitoren
ES2171839T3 (es)	1996-09-05	2002-09-16	Lilly Co Eli	Analogos de carbazol como agonistas adrenergicos selectivos de beta3.
WO1998009632A1 (en)	1996-09-06	1998-03-12	Merck & Co., Inc.	Methods and compositions for treating preterm labor
SE9704644D0 (sv)	1997-12-12	1997-12-12	Astra Ab	New use
US6541669B1 (en)	1998-06-08	2003-04-01	Theravance, Inc.	β2-adrenergic receptor agonists
US6683115B2 (en)	1999-06-02	2004-01-27	Theravance, Inc.	β2-adrenergic receptor agonists
AUPQ407699A0 (en)	1999-11-16	1999-12-09	Fujisawa Pharmaceutical Co., Ltd.	Aminoalcohol derivatives
OA11558A (en)	1999-12-08	2004-06-03	Advanced Medicine Inc	Beta 2-adrenergic receptor agonists.
WO2002012265A1 (en)	2000-08-05	2002-02-14	Glaxo Group Limited	6.ALPHA., 9.ALPHA.-DIFLUORO-17.ALPHA.-`(2-FURANYLCARBOXYL) OXY&excl;-11.BETA.-HYDROXY-16.ALPHA.-METHYL-3-OXO-ANDROST-1,4,-DIENE-17-CARBOTHIOIC ACID S-FLUOROMETHYL ESTER AS AN ANTI-INFLAMMATORY AGENT
GB0103630D0 (en)	2001-02-14	2001-03-28	Glaxo Group Ltd	Chemical compounds
WO2003042160A1 (en)	2001-11-13	2003-05-22	Theravance, Inc.	Aryl aniline beta-2 adrenergic receptor agonists
TWI249515B (en)	2001-11-13	2006-02-21	Theravance Inc	Aryl aniline beta2 adrenergic receptor agonists
US7258118B2 (en)	2002-01-24	2007-08-21	Sofotec Gmbh & Co, Kg	Pharmaceutical powder cartridge, and inhaler equipped with same
PE20040950A1 (es)	2003-02-14	2005-01-01	Theravance Inc	DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
PE20050973A1 (es) *	2003-10-29	2005-11-19	Theravance Inc	Sales de acido naftalen-1,5-disulfonico de un compuesto de 4-amino-1-(piridilmetil)piperidina como antagonistas de receptores muscarinicos
ES2232306B1 (es)	2003-11-10	2006-08-01	Almirall Prodesfarma, S.A.	Nuevos derivados de piridazin-3(2h)-ona.
TW200531692A (en)	2004-01-12	2005-10-01	Theravance Inc	Aryl aniline derivatives as β2 adrenergic receptor agonists
EP1574501A1 (en) *	2004-03-11	2005-09-14	Pfizer Limited	Quinolinone derivatives, pharmaceutical compositions containing them and their use
EP1577291A1 (en)	2004-03-17	2005-09-21	Pfizer Limited	Phenylethanolamine derivatives as beta-2 agonists
PL1730103T3 (pl)	2004-03-23	2010-10-29	Pfizer	Pochodne formamidu użyteczne jako adrenoreceptor
CN1938319B (zh) *	2004-04-09	2010-05-12	韩美药品株式会社	结晶氯吡格雷萘磺酸盐或其水合物、其制备方法及含其的药物组合物
WO2005121065A2 (en)	2004-06-03	2005-12-22	Theravance, Inc.	DIAMINE β2 ADRENERGIC RECEPTOR AGONISTS
JP2008507532A (ja)	2004-07-21	2008-03-13	セラヴァンス，インコーポレーテッド	ジアリールエーテルβ２アドレナリン作用性レセプターアゴニスト
TWI374883B (en)	2004-08-16	2012-10-21	Theravance Inc	Crystalline form of a biphenyl compound
TW200613275A (en) *	2004-08-24	2006-05-01	Recordati Ireland Ltd	Lercanidipine salts
WO2006099166A1 (en) *	2005-03-10	2006-09-21	Theravance, Inc.	Crystalline forms of a biphenyl compound
ES2265276B1 (es)	2005-05-20	2008-02-01	Laboratorios Almirall S.A.	Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2296516B1 (es)	2006-04-27	2009-04-01	Laboratorios Almirall S.A.	Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2302447B1 (es)	2006-10-20	2009-06-12	Laboratorios Almirall S.A.	Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2320961B1 (es)	2007-11-28	2010-03-17	Laboratorios Almirall, S.A.	Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EP2096105A1 (en)	2008-02-28	2009-09-02	Laboratorios Almirall, S.A.	Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor
UY32297A (es)	2008-12-22	2010-05-31	Almirall Sa	Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2221055A1 (en)	2009-02-18	2010-08-25	Almirall, S.A.	5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function
EP2221297A1 (en)	2009-02-18	2010-08-25	Almirall, S.A.	5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one and its use in the treatment of pulmonary diseases
EP2228368A1 (en)	2009-03-12	2010-09-15	Almirall, S.A.	Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one

2007
- 2007-02-09 ES ES200700362A patent/ES2306595B1/es active Active
2008
- 2008-02-07 PE PE2008000273A patent/PE20081752A1/es not_active Application Discontinuation
- 2008-02-07 CL CL200800404A patent/CL2008000404A1/es unknown
- 2008-02-07 PE PE2012001001A patent/PE20121521A1/es not_active Application Discontinuation
- 2008-02-07 AR ARP080100526A patent/AR065247A1/es not_active Application Discontinuation
- 2008-02-08 SI SI200830677T patent/SI2121615T1/sl unknown
- 2008-02-08 ES ES08707620T patent/ES2384905T3/es active Active
- 2008-02-08 CN CN2008800043230A patent/CN101679269B/zh not_active Expired - Fee Related
- 2008-02-08 PL PL08707620T patent/PL2121615T3/pl unknown
- 2008-02-08 DK DK08707620.4T patent/DK2121615T3/da active
- 2008-02-08 RS RS20120226A patent/RS52302B/sr unknown
- 2008-02-08 AT AT08707620T patent/ATE551323T1/de active
- 2008-02-08 BR BRPI0806391A patent/BRPI0806391A8/pt not_active IP Right Cessation
- 2008-02-08 PT PT08707620T patent/PT2121615E/pt unknown
- 2008-02-08 MX MX2009008462A patent/MX2009008462A/es active IP Right Grant
- 2008-02-08 MY MYPI20093274A patent/MY153657A/en unknown
- 2008-02-08 KR KR1020147032769A patent/KR20140140651A/ko not_active Withdrawn
- 2008-02-08 UA UAA200909064A patent/UA97829C2/uk unknown
- 2008-02-08 WO PCT/EP2008/000975 patent/WO2008095720A1/en not_active Ceased
- 2008-02-08 EP EP08707620A patent/EP2121615B1/en active Active
- 2008-02-08 HR HRP20120456AT patent/HRP20120456T1/hr unknown
- 2008-02-08 US US12/526,090 patent/US8283342B2/en not_active Expired - Fee Related
- 2008-02-08 AU AU2008213109A patent/AU2008213109B2/en not_active Ceased
- 2008-02-08 CA CA2677610A patent/CA2677610C/en active Active
- 2008-02-08 NZ NZ578412A patent/NZ578412A/en not_active IP Right Cessation
- 2008-02-08 RU RU2009133442/04A patent/RU2495029C2/ru active
- 2008-02-08 JP JP2009548626A patent/JP5390402B2/ja not_active Expired - Fee Related
- 2008-02-08 KR KR1020097016590A patent/KR101493538B1/ko not_active Expired - Fee Related
- 2008-02-12 TW TW097104853A patent/TWI396535B/zh not_active IP Right Cessation
2009
- 2009-07-10 ZA ZA200904851A patent/ZA200904851B/xx unknown
- 2009-07-16 IL IL199912A patent/IL199912A/en active IP Right Grant
- 2009-08-04 EC EC2009009557A patent/ECSP099557A/es unknown
- 2009-08-06 CO CO09082396A patent/CO6231025A2/es not_active Application Discontinuation
2012
- 2012-06-13 CY CY20121100543T patent/CY1113366T1/el unknown

Also Published As

Publication number	Publication date
JP5390402B2 (ja)	2014-01-15
KR20090111321A (ko)	2009-10-26
SI2121615T1 (sl)	2012-08-31
CN101679269B (zh)	2013-02-13
EP2121615B1 (en)	2012-03-28
US20110195943A9 (en)	2011-08-11
PL2121615T3 (pl)	2012-11-30
BRPI0806391A2 (pt)	2011-09-06
KR20140140651A (ko)	2014-12-09
CO6231025A2 (es)	2010-12-20
TWI396535B (zh)	2013-05-21
CN101679269A (zh)	2010-03-24
BRPI0806391A8 (pt)	2019-10-01
PT2121615E (pt)	2012-06-25
MX2009008462A (es)	2009-09-16
HK1133011A1 (en)	2010-03-12
EP2121615A1 (en)	2009-11-25
ATE551323T1 (de)	2012-04-15
CY1113366T1 (el)	2016-06-22
ES2306595A1 (es)	2008-11-01
AU2008213109B2 (en)	2012-12-06
US8283342B2 (en)	2012-10-09
PE20121521A1 (es)	2012-11-26
RU2009133442A (ru)	2011-03-20
JP2010518038A (ja)	2010-05-27
US20100093681A1 (en)	2010-04-15
KR101493538B1 (ko)	2015-02-13
ZA200904851B (en)	2010-04-28
UA97829C2 (uk)	2012-03-26
RS52302B (sr)	2012-12-31
PE20081752A1 (es)	2008-12-06
IL199912A (en)	2015-08-31
ECSP099557A (es)	2009-09-29
CA2677610C (en)	2016-03-22
HRP20120456T1 (hr)	2012-06-30
NZ578412A (en)	2011-02-25
ES2306595B1 (es)	2009-09-11
DK2121615T3 (da)	2012-07-02
IL199912A0 (en)	2010-04-15
WO2008095720A1 (en)	2008-08-14
AU2008213109A1 (en)	2008-08-14
RU2495029C2 (ru)	2013-10-10
MY153657A (en)	2015-03-13
TW200902001A (en)	2009-01-16
AR065247A1 (es)	2009-05-27
CA2677610A1 (en)	2008-08-14
ES2384905T3 (es)	2012-07-13

Publication	Publication Date	Title
CL2008000404A1 (es)	2008-08-18	Sal cristalina de napadisilato de 5-(2-[[6-(2,2-difluoro-2-feniletoxi)hexil]amino]-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como asma o epoc.
CL2008000307A1 (es)	2008-05-30	Compuestos derivados de cromen-2-ona sustituido; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como ateroesclerosis, asma, rinitis alergica y epoc.
CL2007003635A1 (es)	2008-08-22	Compuestos derivados de 6-amino-purin-8-ona; proceso de preparacion; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades alergicas, virales o cancer.
CL2007002610A1 (es)	2008-02-01	Compuestos derivados de bipiridina sustituida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o la profilaxis de enfermedades tales como hipertonia, diabetes, infarto de miocardio, entre otras.
CL2007003765A1 (es)	2008-08-22	Compuestos derivados de 2-oxo-4-hidroxi-benzotiazol; procesode preparacion; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, bronquitis, asma y bronquiectasias.
CL2007000161A1 (es)	2008-05-30	Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
CL2008001304A1 (es)	2008-09-22	Compuestos derivados de indol sustituido, inhibidores de la proteina activadora de la 5-lipoxigenasa (flap); composicion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, enfermedad cardiovascular e inflamacion.
CL2008000875A1 (es)	2008-10-03	Compuestos derivados de imidazolidin-2-ona; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento y/o profilaxis de enfermedades tales como dislipidemia, diabetes, enfermedades inflamatorias, entre otras.
CL2007002327A1 (es)	2008-05-16	Compuestos derivados de fenil-imidazol sustituido; composicion farmaceutica; y uso en el tratamiento del vhc.
CL2008000592A1 (es)	2008-09-12	Compuestos derivados de pirrol sustituido, supresores de la secrecion de acidos; composicion farmaceutica; y uso en el tratamiento o profilaxis en enfermedades tales como ulcera peptica, gastritis, esofagitis, entre otras.
CL2008001994A1 (es)	2008-09-22	Compuestos derivados de pirazin-2-ona; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, aterosclerosis, hipertension, entre otras.
IL182010A0 (en)	2007-07-24	Heteroaryl compounds for use as betamimetics in the treatment of respiratory diseases
IL199152A (en)	2015-11-30	Annals 2 - (piperidine-4-ram) -4-phenoxy or phenylamino-pyrimidine, containing and containing pharmaceutical preparations for the preparation of viral infections
CL2007000806A1 (es)	2008-05-30	Compuestos derivados de heteropentaciclos sustituidos; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2013003372A1 (es)	2014-07-25	Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
CL2008000690A1 (es)	2008-09-12	Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras.
CL2007002708A1 (es)	2008-04-04	Compuestos derivados de pirrolo[2,3-b]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, caquexia, trastornos inflamatorios, entre otros.
CL2012001464A1 (es)	2014-03-07	Compuestos derivados de (2-amino-5,5-difluor-5,6-dihidro-4h-[1,3]oxazin-4-il)-fenilamida, inhibidores bace1 y/o bace2; composicion farmaceutica; procedimiento de preparacion; y uso en el tratamiento terapeutico y/o profilactico de enfermedades tales como alzheimer y diabetes.
CL2008000791A1 (es)	2008-05-30	Compuestos derivados de 2-amino-5-(4-difluorometoxi-fenil)-5-fenil-imidazolidin-4-ona; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una enfermedad asociada con la actividad bace excesiva, tales como enferm
CL2012003026A1 (es)	2013-02-01	Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad.
CL2007003672A1 (es)	2008-07-25	Compuestos derivados de heteroaril-pirrolidinil-cetona y heteroaril-piperidinil-cetona; composicion farmaceutica; y uso en el tratamiento de la depresion y ansiedad.
CL2008001025A1 (es)	2008-10-17	Compuestos derivados de pirimido[5,4-d]pirimidina-2,4,6,8-tetraona; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como trastorno metabolico, dislipidemia y cancer.
CL2007002689A1 (es)	2008-04-18	Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
CL2007003754A1 (es)	2008-08-22	Compuestos derivados de aril(heteroaril)alquil-amina; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como bronquitis, enfisema pulmonar y epoc.
CL2007003038A1 (es)	2008-06-06	Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.